Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients.

The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.

Additionally, patients administered with PBF-680 showed statistically significant improvement compared to placebo treated patients in most of the secondary endpoints evaluated, including FEV1 AUC on day 15 and the Asthma Control Questionnaire.

Remarkably, PBF-680 treatment caused a robust decrease in eosinophil counts at day 15, which recover to normal values two weeks later.

No serious adverse events were reported in the trial, demonstrating once again the very good safety and tolerability profile of the compound.

News

Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients.

Related News

XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma

PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).

November 10th. 2021. Palobiofarma announces positive results in the Phase IIa clinical trial evaluating it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis.

Palobiofarma announces the completion the Phase II clinical trial with its investigational therapy PBF-680 in chronic obstructive pulmonary disease (COPD) patients.

Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting.

Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome

September 09. 2021. Palobiofarma announces the finalization of the Phase IIa clinical trial of it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis

Palobiofarma S.L. Receives Rare Pediatric Disease Designation from the U.S. FDA for PBF-999 for the Treatment of Prader-Willi Syndrome

Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team

June 8th, 2020: Palobiofarma joins the fight against the Covid-19 pandemia